The primary efficacy endpoint will be FEV1 area under the curve for the time period 0 to 12 hours (FEV1 AUC0-12) measured after 6 weeks of treatment, at the final study visit (Visit 4). [clinicaltrials_resource:02d4c8fc8a210ff2b247f89d1956ad8b]

The primary efficacy endpoint will be FEV1 area under the curve for the time period 0 to 12 hours (FEV1 AUC0-12) measured after 6 weeks of treatment, at the final study visit (Visit 4). [clinicaltrials_resource:02d4c8fc8a210ff2b247f89d1956ad8b]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:02d4c8fc8a210ff2b247f89d1956ad8b

The primary efficacy endpoint will be FEV1 area under the curve for the time period 0 to 12 hours (FEV1 AUC0-12) measured after 6 weeks of treatment, at the final study visit (Visit 4). [clinicaltrials_resource:02d4c8fc8a210ff2b247f89d1956ad8b]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:02d4c8fc8a210ff2b247f89d1956ad8b
Bio2RDF identifier
02d4c8fc8a210ff2b247f89d1956ad8b
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:02d4c8fc8a210ff2b247f89d1956ad8b
measure [clinicaltrials_vocabulary:measure]
The primary efficacy endpoint ...... e final study visit (Visit 4).
identifier
clinicaltrials_resource:02d4c8fc8a210ff2b247f89d1956ad8b
title
The primary efficacy endpoint ...... e final study visit (Visit 4).
@en
inDataset
type
label
The primary efficacy endpoint ...... 4c8fc8a210ff2b247f89d1956ad8b]
@en